CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Documentation of awarded credit is provided for participants in exchange for completed activity evaluations.
OVERVIEW
Treatment innovations in the field of interventional cardiology have changed the lives of heart patients around the world. Transcatheter aortic valve replacement (TAVR) is a less invasive alternative to traditional valve replacement surgery and is already being used successfully in high-risk patients. This webcast discussion will move beyond high-risk patients and explore the new boundaries of transcatheter therapy. Participants will learn from discussions about considerations for low-risk patient populations, treatment decision making, and recent clinical trial data.
LEARNING OBJECTIVES
By the end of this activity, participants should be able to:
1) Identify results and endpoints including mortality, stroke, re-hospitalization, and durability.
2) Describe developments in recent TAVR low-risk studies.
3) Summarize perspectives on shared decision making for the heart team.
TARGET AUDIENCE
This activity is designed for interventional cardiologists, cardiac surgeons, clinical cardiologists, vascular medicine specialists, and other healthcare professionals.
ACTIVITY EVALUATION
Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.
DISCLOSURE STATEMENT
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage and/or off-label product use is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.
Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty not complying with this policy are not permitted to participate in this activity.
FACULTY DISCLOSURE SUMMARY
KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E/S/O) Equity/Stock(s)/Options (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit
Howard C. Herrmann: (G/R) Abbott Vascular, Ancora Heart, Boston Scientific Corporation, (G/R) (C/H/S) Edwards Lifesciences, Medtronic
Jeffrey J. Popma: (G/R) Abbott Vascular, Abiomed, Biotronik, Cook Medical, Medtronic, Highlife Medical, (G/R) (C/H/S) Boston Scientific Corporation, Edwards Lifesciences
Michael J. Reardon: (C/H/S) Medtronic
Mathew Williams: (G/R) Edwards Lifesciences, HLT, Abbott Vascular, (G/R) (C/H/S) Medtronic, Boston Scientific Corporation, (E) MincroInternventional, Thubrikar
Planning Committee
Robert Blanco (Planner)
(S) Cardiovascular Research Foundation
ACTIVITY SPONSORSHIP AND SUPPORT
This program is sponsored by the Cardiovascular Research Foundation. It is supported through an educational grant from Medtronic, Inc. and was developed without influence from commercial supporters.
HOW TO RECEIVE CME CREDIT
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Robert Blanco at rblanco@crf.org .